Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

Novartis

Status and phase: Completed; Phase 4

Conditions: Controlled Hypertension; Osteoarthritis

Treatments: Drug: lumiracoxib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00267176

CCOX189A2428

Details and patient eligibility

About

This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Osteoarthritis of the hand, hip, knee or spine
• High blood pressure (<140/ 90 mmHg) which is controlled by antihypertensive medication(s).

Exclusion criteria

• Evidence or history of any cardiac and cerebral thrombotic/ ischemic diseases and/ or events

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind